9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium

By Kindler Hedy   Avadhani Anjali   Wade-Oliver Kurombi   Karrison Theodore   Mani Sridhar   Vokes Everett  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 323-327

Springer Publishing Company

Access to resources Recommend Favorite

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

By Wong R.   Baetz T.   Krahn M.   Biagi J.   Wainman N.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 347-351

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial

By Galanis Evanthia   Buckner Jan   Maurer Matthew   Reid Joel   Kuffel Mary   Ames Matthew   Scheithauer Bernd   Hammack Julie   Pipoly George   Kuross Steven  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 495-503

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

By Gomez-Abuin Gonzalo   Winquist Eric   Stadler Walter   Pond Greg   Degendorfer Pamela   Wright John   Moore Malcolm  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 181-185

Springer Publishing Company

Access to resources Recommend Favorite